Literature DB >> 11455528

HIV-associated nephropathy: an urban epidemic.

M Monahan1, N Tanji, P E Klotman.   

Abstract

Human immunodeficiency virus-associated nephropathy (HIVAN) is the most common form of chronic renal disease in HIV-1-seropositive patients. Over 85% of cases of HIVAN occur in African-American patients and it is the third leading cause of ESRD in blacks age 20 to 64. Changes in incidence rates of HIVAN have coincided with changes in AIDS incidence rates. The demographics of the AIDS/HIV-1 epidemic indicate that the risk pool for HIVAN will continue to grow and that urban Nephrology centers will continue to see high rates of HIVAN. In addition, improvements in survival rates of HIV-1-seropositive patients on hemodialysis and improved treatment of HIVAN with highly active antiretroviral therapy (HAART) and angiotensin-converting enzyme (ACE)-inhibitors will result in an increased prevalence of HIVAN in the end-stage renal disease (ESRD) and pre-ESRD patient populations. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11455528     DOI: 10.1053/snep.2001.23771

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  12 in total

1.  Race and kidney disease: the scope of the problem.

Authors:  Keith C Norris; Lawrence Y Agodoa
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

2.  Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland.

Authors:  Mohamed G Atta; Derek M Fine; Gregory D Kirk; Shruti H Mehta; Richard D Moore; Gregory M Lucas
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

Review 3.  HIV and the kidney: a status report after 20 years.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

4.  Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway.

Authors:  John Cijiang He; Ting-Chi Lu; Margaret Fleet; Masaaki Sunamoto; Mohammad Husain; Wei Fang; Susana Neves; Yibang Chen; Stuart Shankland; Ravi Iyengar; Paul E Klotman
Journal:  J Am Soc Nephrol       Date:  2006-12-20       Impact factor: 10.121

5.  Outcomes of kidney transplantation in HIV-infected recipients.

Authors:  Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland
Journal:  N Engl J Med       Date:  2010-11-18       Impact factor: 91.245

Review 6.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Renal transplantation in patients with HIV.

Authors:  Lynda A Frassetto; Clara Tan-Tam; Peter G Stock
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

8.  Immunotactoid glomerulonephritis in a child with HIV infection: a case report.

Authors:  Gertruida van Biljon; Melanie Louw; Leonora Dreyer
Journal:  Pediatr Nephrol       Date:  2007-04-25       Impact factor: 3.714

9.  Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.

Authors:  L M Kucirka; C M Durand; S Bae; R K Avery; J E Locke; B J Orandi; M McAdams-DeMarco; M E Grams; D L Segev
Journal:  Am J Transplant       Date:  2016-05-25       Impact factor: 8.086

10.  Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3.

Authors:  Ali G Gharavi; Tariq Ahmad; Robert D Wong; Roozbeh Hooshyar; Janene Vaughn; Sarah Oller; Rachelle Z Frankel; Leslie A Bruggeman; Vivette D D'Agati; Paul E Klotman; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.